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Antimicrobial proteinaceous compounds such as bacteriocins or bacteriocin-like compounds produced 
by Lactobacillus acidophilus are largely known and have been found to have potent antimicrobial 
activities toward closely related bacteria and undesirable harmful microorganisms. They are useful in 
the fields of food preservation or safety, health care, and pharmaceutical applications. The inhibition 
activity of these substances has been reported to be strain-dependent. Binding to the epithelial cell on 
the gastrointestinal surfaces is one of the important factors of resident microflora to colonize the 
intestine. Certain L. acidophilus strains are able to produce substances that compete and prevent 
pathogenic bacteria from adhering to the receptors on epithelial cells of intestinal surfaces. The 
potential probiotic effects of L. acidophilus is well known in the human ecosystem and their production 
of antimicrobial peptides can contribute to elucidate the precise mechanisms by which L. acidophilus 
can dominate the intestinal microbiota and achieve their probiotic function. This paper presents a review 
of the antimicrobial proteinaceous compounds produced by various acidophilus strains, the attempts 
made to purify them, their characterization and useful applications. 
 





Lactobacillus acidophilus nonpathogenic and a member 
of the normal intestinal microflora is widely used in fer-
mented dairy products and is of considerable industrial 
and medical interest because it has been reported to aid 
in the reduction of the levels of harmful bacteria and 
yeasts in the small intestine and to produce lactase, an 
enzyme which is important for the digestion of milk 
(Deraz et al., 2007). Therefore L. acidophilus group of 
lactic acid bacteria (LAB) is added as dietary adjuncts to 
commercial fermented milk products and the intake of 
these bacteria may have beneficial effects on human 
health (Kawai et al., 2001 ). 
The properties of L. acidophilus have been investigated 
in order to establish its specific role in the complex micro-




*Corresponding author. E-mail: ypwang40@yahoo.com. 
(Sarra et al., 1980) The L. acidophilus has been consi- 
dered to be the predominant lactobacillus in the intestinal 
tract of healthy humans (Ray, 1996). L. acidophilus 
strains have been widely utilized as a dairy starter culture 
for their therapeutic activities associated with an intestinal 
microbial balance, and has been used in fermented foods, 
and as a probiotic in dietary supplements (Sanders and 
Klaenhammer, 2001). Oda et al. (1994) also showed that 
L. acidophilus increased iron bioavailability of fermented 
milk in animal model. Recent in vitro studies showed that 
L. acidophilus is a strong Th1 cytokine (IL-12, IFN-) 
inducer (Gackowska et al., 2006). L. acidophilus signifi-
cantly up-regulated surface markers on dendritic cells 
(DCs), including HLA-DR, CD40, CD86 and CD83 
(Zeuthen et al., 2006). 
There is an increasing interest in the research of 
antimicrobial peptides (bacteriocins and bacteriocin-like 
compounds) produced by lactic acid bacteria (LAB) 
because of their potential use as antimicrobial agents  for 




improving the safety of food products (Yildirim et al., 
1999). Among Lactobacilli, strains belonging to species of 
the L. acidophilus complexes are most frequently used as 
probiotics (Klaenhammer and Kullen, 1999). Bacteriocin 
production is often proposed as a beneficial characteristic 
of probiotic bacteria (Klaenhammer and Kullen, 1999; 
Fooks and Gibson, 2002). It may contribute to the 
colonisation resistance of the host and its protection 
against gastroin-testinal pathogens (Reid, et al., 2001; 
Bourlioux, 1997). As the bacteriocin producing strain L. 
acidophilus IBB 801, a dairy isolate, displays antibacterial 
activity against Escherichia coli and Salmonella, the 
authors suggested that it may have potential as a 
probiotic (Zamfir et al., 1999). Numerous reports have 
proved the ability of L. acidophilus strains to produce 
bacteriocins (Chumchal-ova et al., 2004). L. acidophilus 
strains exhibiting anta-gonistic activity towards certain 
types of psychrotrophic microorganisms such as Listeria 
monocytogenes, Bacillus cereus, and Clostridium sp. are 
especially impor-tant as these microorganisms even at 
low levels in food pose a significant spoilage and public 
health threat (Kantani et al., 1995 Bogovic-Matijasic et al., 
1998). Bac-teriocins are lethal to closely related bacterio-
cin-related species, food-borne pathogens and spoilage 
bacteria (Tagg et al., 1976; Klaenhammer, 1993). 
Among the Lactobacillus species, L. acidophilus strains 
have been extensively utilized as probiotic cultures in 
dairy and pharmaceutical products and numerous reports 
have proved its ability to produce bacteriocins (De Souza 
et al., 2005), yet no review has been published summari-
zing its bacteriocin production. Therefore, the purpose of 
this paper is to have an overview and summarize the 
study of previous authors on bacteriocin producing L. 
acidophilus strains. 
Since Metchnikoff (1908) proposed a role for 
lactobacilli in suppressing undesirable intestinal micro-
flora, numerous researchers have investigated the 
antimicrobial activities of L. acidophilus. Broad spectrum 
inhibition has been clearly demonstrated for organic acids 
and hydro-gen peroxide produced by L. acidophilus 
(Gilliland and Speck 1977; Tramer 1966). In addition, a 
number of reports suggest that antimicrobial proteins, or 
bacte-riocins, either mediate or facilitate antagonism by L. 
acidophilus (Gilliland and Speck 1977; Hamdan and 
Mikolajcik. 1974; Hosono et al., 1977; Morin et al., 1980). 
Vincent et al. (1959) first described a bacteriocin-type 
inhibitor produced in aged liver veal agar cultures of L. 
acidophilus. Crude "lactocidin" was nonvolatile, non-diali-
zable, insensitive to catalyze, active at neutral pH and 
displayed inhibitory activity against numerous genera, 
including Proteus, Salmonella, Escherichia, Staphylo-
coccus, Bacillus, Streptococcus, and L. actobacillus. No 
further studies on lactocidin, or similar broad-spectrum 
bacteriocins produced by L. acidophilus have been 
reported. However previous studies of antagonism by L. 
acidophilus do not specifically address, identify, or con- 








BACTERIOCIN PRODUCTION AND ITS GENERAL 
PROPERTIES 
 
The first study on the production of bacteriocins by L. 
acidophilus has been reported by Barefoot and 
Klaenhammer (1983) who mentioned that L. acidophilus 
produces bacteriocin which he named as Lactacin B. L. 
acidophilus was restricted to selected members of the 
family Lactobacilliaceae under conditions eliminating the 
effects of organic acids and hydrogen peroxide proving 
that antibacterial activity was only due to bacteriocin. 
Moreover, in contrast to previous reports, no broad 
spectrum inhibitory activity was observed for either strain 
when hydrogen peroxide and organic acids were elimina-
ted (Barefoot and Klaenhammer, 1983). Production of 
lactatin B was pH dependent, with maximum activity 
detected in broth cultures maintained at pH 6 (Barefoot 
and Klaenhammer, 1984). Chromatofocusing and gel 
filtration high performance liquid chromatography of cell-
free filtrates yielded a protein with a pH of 4.1 and a 
molecular size of 58 kDa that induced lactacin B pro-
duction (Barefoot and Klaenhammer, 1994). Purified 
lactacin B was stable under a variety of conditions. Full 
activity was retained after treatment at 100°C for 3 min at 
pH 5 or 8.6 in the presence of 1.0% SDS. Addition of 1% 
2-mercaptoethanol during the heating step did not de-
crease activity (Barefoot and Klaenhammer, 1984). Table 
1 represents a summary of bacteriocin or bacteriocin-like 
compounds from acidophilus bacteria that have been 
purified and named.  
Lactacin F, produced by L. acidophilus 11088 (NCK88), 
is more heat resistant and exhibits a broader spectrum of 
activity than lactacin B inhibiting also L. acidophilus, L. 
fermentum, and Enterococcus faecalis in addition to the 
other lactacin B indicators (Muriana and Klaenhammer, 
1991). Production of lactacin F is also pH dependent; 
maximum levels of lactacin F are obtained in MRS broth 
maintained at pH 7.0, whereas negligible activity is 
produced in fermentors held at pH 7.5 or 6.5. Purification 
by ammonium sulfate precipitation, gel filtration, and high 
performance liquid chromatography resulted in a 474 fold 
increase in specific activity of lactacin F. The purified bac-
teriocin was identified as a 2.5 kDa peptide by (SDS-
PAGE). Composition analysis indicates that lactacin F 
may contain as many as 56 amino acid residues (Muria-
na and Kalenhammer 1991). L. acidophilus LAPT 1060 
produces heat-labile bacteriocin contrary to lactacin B 
and Lactacin F. The agent was sensitive to proteolytic 
enzymes and heat (10 min at 60°C) and is a bacteriocin 
and designated acidophilucin A (Toba et al., 1991). The 
genetic determinant for bacteriocin production can be 
either plasmid or chromosomally encoded (Klaenhammer, 
1993). L. acidophilus TK8912 produces a plasmid asso-
ciated bacteriocin, termed as acidocin 8912 which is heat  




Table 1. Summary of named bacteriocin purified from acidophilus bacteria. 
 
Species Peptide Reference 
L. cidophilu N lactacin B Barefoot et al. (1983) 
L. cidophilu 11088 lactacin F Muriana and Klaenhammer (1991) 
L. cidophilu LAPT 1060 Acidophilucin A Toba et al. (1991) 
L. cidophilu. TK8912 Acidocin 8912 Kanatani et al. (1992) 
L. cidophilu M46 Acidocin B ten Brink et al.  (1994) 
L cidophilu TK9201  Acidocin A Kantani et al. (1995) 
L. acidophilus CH5 Acidocin B Chumchalova et al. (995) 
L. acidophilus JCM 1229 Acidocin JI229 Tahara and Kanatan (1996) 
L. acidophilus JCM 1132 Acidocin JII32 Tahara et al. (1996) 
L. acidophilus LA-1 Acidophilicin LA-1 Dave and Shah (1997) 
L. acidophilus L. AcidophilusLF221 Acidocins LF221A & B Bogovic-Matijasˇic et al. 1998) 
L. acidophilus IB801 Acidophilin 801 Zamfir et al. (1999) 
L. acidophilus DSM20079 Acidocin D20079 Deraz et al. (2005) 
L. acidophilus AA11 Acidocin D20079 Abo-Amer (2007) 




stable bacteriocin and has been shown to be bactericidal 
on a limited number of micro-organisms. Of all conditions 
tested, the production of acidocin 8912 was maximized at 
30°C in MRS broth (Tahara et al. 1992; Kanatani et al., 
1992; Tahara et al., 1996). 
Acidocin B is bacteriocin produced by L. acidophilus 
M46, which combines the inhibition of Clostridium 
sporogenes with a very narrow activity spectrum within 
the genus Lactobacillus. Acidocin B is sensitive to trypsin, 
heat stable (80°C for 20 min) and can be extracted from 
the culture supernatant fluid with butanol. Native acidocin 
B occurs as a large molecular weight complex (100 kDa), 
while with SDS-PAGE the partly purified activity migrates 
as a peptide of 2.4 kDa. Optimization of the cultivation 
conditions resulted in an eight-fold increase of the 
amount of acidocin B produced during growth. Genetic 
studies revealed that acidocin B production by L. 
acidophilus M46 is linked to the presence of 14 kb 
plasmid (Ten Brink et al., 1994; Van der Vossen et al., 
1994). L. acidophilus CH5, the strain isolated from a com-
mercial dairy starter culture, produced a bacteriocin 
named acidocin CH5 with suitable properties for the use 
in food industry. Crude acidocin CH5 was relatively heat 
stable (retaining 25% of activity after 121°C for 20 min), 
effective in broad pH range from three to nine, insensitive 
to catalyze and sensitive to proteolytic and glycosidic 
enzymes (Chumchalova et al., 1995). Acidocin CH5 
exerted wide inhibitory activity spectrum against Gram 
positive bacteria and food spoilage bacteria, Arthrobacter 
sp., Bacillus sp. and Corynebacterium sp. Table 2 pre-
sents a summary of the acidophilus bacterial strains 
studied and their spectrum of inhibition towards most 
sensitive bacteria. Characterization of CH5 bacteriocin 
revealed that it belongs to the class II bacteriocins with 
identical N-terminal amino acid sequence described in 
the literature previously (Chumchalova´ et al., 1995). 
Acidocin J1229 produced by L. acidophilus JCM 1229 
was heat stable bacteriocin and its production was in 
MRS broth was pH dependent, with maximum activity 
detected in broth culture maintained at pH 5.0. The 
sequence of the first 24 amino acid residues of the N 
terminus of acidocin 51229 was determined. The mole-
cular mass of acidocin J1229 as determined by mass 
spectrometry was 6301 Da (Tahara and Kanatani, 1996a). 
L. acidophilus JCM 1132 produces a heat-stable, two 
component bacteriocin designated acidocin J1132 that 
has a narrow inhibitory spectrum. Acidocin J1132 activity 
was associated with two components, termed  and . 
On the basis of N-terminal amino acid sequencing and 
the molecular masses of  and  components, it is inter-
preted that the compounds differ by an additional glycine 
residue in the  component (Tahara and Kanatani, 1996). 
The crude bacteriocin produced by L. acidophilus LA-1 
was stable over a wide range of pH and temperature, 
was active after autoclaving and was not affected by sto-
rage at 37, 4 or 18°C. The production of bacteriocin 
occurred in log phase and was highest in the pH range of 
5.5-6. Activity declined considerably when cell entered 
into death phase (Dave and Shah, 1997). L. acidophilus 
LF221 produced at least two bacteriocins and N-terminal 
amino acid composition of bacteriocins A and B was 
found to be different from those of the other bacteriocins, 
indicating that the two bacteriocins were novel. They 
were named acidocin LF221 A and acidocin LF221 B. 
Besides some lactic acid bacteria, the following species 
were inhibited: B. cereus, Clostridium sp., Listeria inno-
cua, Staphylococcus aureus, Streptococcus (Bogovic-
Matijasic et al., 1998)  
A bacteriocin, designated acidophilin 801, produced by 
L. acidophilus IBB 801, has been partially characterized. 
It is sensitive to several proteases and inhibition occurs 
under conditions which  eliminate  the  effects  of  organic  




Table 2. Spectrum of antimicrobial activity of the proteinaceous inhibitory compounds obtained from acidophilus bacteria 
 
Species Inhibitory spectrum* Reference 
L. acidophilus N Active against member of lactobacillaceae Barefoot et al. (1983)  
L. acidophilus 11088 lactobacilli as well as Enterococcus faecalis Muriana and Klaenhammer (1991) 
L. acidophilus LAPT 1060 L delbrueckii, L. helveticus Toba et al. (1991) 
L. acidophilus TK8912 Lactobacillus and Lactoccus sp. Kanatani et al. (1992), Tahara et al.  (1996) 
L. acidophilus M46 Lactobacillus fermentum, Clostridium sporogenes Ten Brink et al.  (1994) 
L. acidophilus CH5 Inhibiting strains of the geni Lactobacillus, Bacillus, Micrococcus and Corynebacterium Chumchalova et al. (1995) 
L. acidophilus TK9201 closely related lactic acid bacteria and Listeria monocytogenes Kantani et al. (1995) 
L. acidophilus JCM 1229 Lactobacillus sp. and Lactococcus sp. Tahara and Kanatan (1996) 
L. acidophilus JCM 1132 Only against Lactobacillus sp. Tahara et al (1996) 
L. acidophilus LA-1 Some Species of  L. delbrucki and L. casei, L. jugurti Dave and Shah (1997) 
L. acidophilus LF221 Besides some lactic acid bacteria, B. cereus, Clostridium sp., L.  innocua, S. aureus Bogovic-Matijasic et al. (1998) 
L. acidophilus IBB 801 only related lactobacilli, E. coli  and S. panama Zamfir et al. (1999) 
L. acidophilus 30SC Genus Lactobacilli, B. cereus, B. subtilis and Listeria ivanovii Oh et al. (2000) 
L. acidophilus YIT 0154 various species of Lactobacillus including L. acidophilus itself  Yamato et al. (2003) 
L. acidophilus DSM 20079 Against Lactobacillus sp. including L. sakei Deraz et al. (2005) 
L. acidophilus AA11 salmonella, shigella, E. coli  S. aureus, B. cereus, B. subtilis  Abo-Amer (2007) 
L. acidophilus GP1B Shigella, E. coli, P. aeruginosa, L. Monocytogenes Yersinia enterocolitica Kyoung-Sik  et al. (2007) 
 




acids and hydrogen peroxide. Like most of the 
known bacteriocins produced by L. acidophilus 
strains, acidophilin 801 is a heat stable and low 
molecular-mass (less than 6500 Da) peptide 
bacteriocin. Acidophilin 801 displayed a concen-
tration dependent bactericidal effect towards a 
bacteriocin sensitive strain (L. helveticus 102) 
without causing concomitant cell lysis of the 
indicator cells. Amino acid composition analysis of 
acidophilin 801 revealed a strongly hydrophobic 
peptide. Taking all these biochemical characteris-
tics into consideration, acidophilin 801 produced 
by L. acidophilus IBB 801 appears to belong to 
the class II lactic acid bacterium bacteriocins 
according to the classification of Klaenhammer 
(Zamfir et al., 1999). The bacteriocin produced by 
L. acidophilus 30SC displays antimicrobial effects 
on bacteria such as Listeria and Bacillus species; 
spore-forming bacteria, B. cereus and B. subtilis 
were sensitive to the bacteriocin produced by L. 
acidophilus 30SC. The L. acidophilus 30SC 
bacteriocin was active over a wide range of pH, 
and was stable to various heat treatments. The 
loss of antimicrobial activity following treatment 
with proteinase K and proteinase E indicated that 
the active component secreted extracellullarly by 
L. acidophilus 30SC was proteinaceous in nature. 
The molecular mass of the L. acidophilus 30SC 
bacteriocin was estimated at 3.5 kDa (Oh et al., 
2000). L. acidophilus YIT 0154 was found to 
produce a bacteriocin-like substance in the culture 
filtrate. The substance produced in growth asso-
ciated manner, showed heat stability at neutral 
and acidic pH and exhibited antibacterial activity 
against various species of Lactobacillus including 
L. acidophilus itself. The molecular weight of the 
substance was in the range of 6.2–9.5 kDa. N-
terminal amino acid sequence analysis suggests 
that the substance may belong to class II b 
bacteriocin (Yamato et al., 2003). L. acidophilus 
DSM 20079 is the producer of a novel bacteriocin 
termed acidocin D20079. Like many other 
bacteriocins from the L. acidophilus group 
(Kanatani et al., 1992; Tahara and Kanatani, 
1996a; Tahara et al., 1996b; Zamfir et al., 1999), 
acidocin 20079 has a rather narrow inhibition 
spectrum, in principle restricting its action to other 
strains of Lactobacilli. This antimicrobial peptide 
was extremely heat stable (30 min at 121 C) and 
was active over a wide pH range. It was found to 





pepsin, papain, and proteinase K). Mass spectrometry 
was used to determine the molecular mass of the peptide 
6.6 kDa (Deraz et al., 2005, 2007). L. acidophilus AA11 
produced higher antimicrobial activity with a wide range 
of inhibition. The agent AA11 was sensitive to proteolytic 
enzymes and retained full activity after 30 min at 100oC. 
Activity against sensitive cells was bactericidal but not 
bacteriolytic. 12% SDS-PAGE analysis of 40% ammo-
nium sulphate precipitated agent showed two peptides 
with molecular weights of 36 and ~29 kDa. No plasmid 
was identified in L. acidophilus AA11 indicating that the 
genes encoding the inhibitory agent were located on the 
chromosome (Abo-Amer, 2007). Acidocin 1B, a bacte-
riocin produced by L. acidophilus GP1B, exhibited 
profound inhibitory activity against a variety of LAB and 
pathogens, including Gram negative bacteria. It retained 
approximately 67% of the initial activity after storage for 
30 days at 4ºC and 50% of its initial activity after 30 days 
at 25 and 37ºC. The molecular mass of acidocin 1B was 
estimated to be 4,214.65 Da by mass spectrometry. 
Plasmid curing results indicated that a plasmid, desig-
nated as pLA1B, seemed to be responsible for acidocin 
1B production (Kyoung-Sik et al., 2007). 
 
 
PURIFICATION OF ACIDOPHILUS BACTERIOCIN 
 
Lactacin B was purified by ion-exchange chromatography, 
ultrafiltration, and successive gel filtrations in the 
presence of 8 M urea and then 0.1% sodium dodecyl 
sulfate (Barefoot and Klaenhammer, 1984). Strong 
hydrophobicity is a characteristic property of the class II 
peptide bacteriocins. For instance, the proportion of 
hydrophobic amino acids in the L. acidophilus group 
bacteriocins, namely acidophilin 801, gassericin A, 
lactobin A and lactacin F, amounts to 50.8, 45.7, 38.0 
and 29.0%, respectively (Tahara and Kanatani, 1996; 
Tahara et al., 1996b; Nissen-Meyer and Nes, 1997). This 
strong hydrophobic character is one of the main reasons 
why bacteriocin purification is tedious and cumbersome. 
The number of chromatographic steps varies from three 
or more (e.g. acidocin LF221A and B; Bogovic-Matijasic 
et al. 1998) to only one after concentration of the 
bacteriocin from the cell-free culture supernatant fluid 
either via ammonium sulphate precipitation (e.g. lactacin 
F; Muriana and Klaenhammer, 1991) or through 
ammonium sulphate precipitation followed by chloroform/ 
methanol extraction (Zamfir et al., 1999). The lactacin F 
was isolated as a floating pellet from culture supernatants 
brought to 35 to 40% saturation with ammonium sulfate. 
Purification by ammonium sulfate precipitation, gel 
filtration, and high performance liquid chromatography 
resulted in a 474 fold increase in specific activity of 
lactacin F (Muriana and Klaenhammer, 1991).  
Acidocin J1229 was purified by ammonium sulphate 
precipitation and sequential cation exchange and reversed-
phase chromatography. These purification steps  resulted 




in more than 80 fold increase in the specific activity and a 
recovery of 2% of the activity (Tahar and Kanatani, 1996). 
Acidocin J1132 was purified by ammonium sulfate 
precipitation and sequential cation exchange and 
reversed phase chromatography. These purification steps 
resulted in a more than 280 fold increase in the specific 
activity and a recovery of 5% of the activity (Tahar and 
Kanatani, 1996). The cell-free culture supernatant fluid 
(1600 AU ml-1) was precipitated with 40% ammonium 
sulphate saturation. The bacteriocin activity of the pellicle 
increased to 25600 AUml-1. After chloroform/methanol 
extraction, the activity of the precipitate, re-dissolved in 
ultra pure water, was 51200 AUml-1. This material was 
considered to be a partially purified bacteriocin 
preparation. The partially purified bacteriocin was further 
purified by reversed phase FPLC (Zamfir et al., 1999). 
Acidocin CH5 was purified using combinations of 
chromatographic methods based on hydrophobic and 
cation exchange principles. The recovery of bacteriocin 
activity was very low in all fractions. The purification 
procedure resulted in a more than 49 fold increase in the 
specific activity. RP-HPLC on C4 reverse phase column, 
the final purification step, resulted in a peak which 
followed a major protein peak. Acidocin CH5 was purified 
and eluted from the reversed phase column at about 83% 
of ethanol (Chumchalav et al., 2004). During purification 
of the L. acidophilus DSM 20079 peptide, optimal 
recovery was achieved with ammonium sulphate precipi-
tation followed by two chromatographic steps that is by 
using CM Sepharose column and by Octyl Sepharose 
column. The recovery after each of these steps is 
comparable to results for bacteriocins from other 
Lactobacilli, but the advantage here is that the procedure 
is relatively short (Deraz et al., 2005). Acidocin bac-
teriocin activity was eluted from Octyl sepharose CL-4B 
at approximately 45 to 50% ethanol and then from the 
C18 Sep-Pak cartridge at 60% methanol. The final 
purification step by HPLC gel filtration yielded a single 
main peak of the acidocin 1B (Kyoung-Sik et al., 2007). 
 
 
MODE OF ACTION OF ACIDOPHILUS BACTERIOCIN 
 
To test for a bactericidal or bacteriolytic mode of action, 
we investigated the effects of lactacin B on the viability 
and lysis of L. leichmannii 4797. The addition of 
increasing concentrations of lactacin B to L. Ieichmannii 
4797 cells resulted in proportional increases in cell death. 
According to a single hit mechanism for bacteriocin action, 
bacteriocins sequentially adsorb to, penetrate, and kill 
sensitive cells. Lactacin B adsorbed to sensitive cells and 
acted in a single hit fashion characteristic of bacteriocinic 
proteins (Barefoot and Kaenhammer, 1983). Acidocin B 
has bactericidal effect on the target strain as the optical 
density remained constant, indicating that lysis did not 
occur (Ten brink et al., 1994). Acidocin J1229 is a pore 
forming bacteriocin that creates cell membrane  channels 




through the ‘barrel-stave’ mechanism. Taken together, 
acidocin J1229 has a bactericidal effect on sensitive 
organisms by dissipating the PMF, inhibiting the transport 
of amino acids, and causing the leakage of essential 
compounds by the formation of pores in the cytoplasmic 
membrane (Tahara and Kanatani, 1996). Acidocin J1132 
has a bactericidal effect on sensitive organisms by 
dissipating the PMF, inhibiting the transport of amino 
acids, and causing the leakage of essential compounds 
by the formation of pores in the cytoplasmic membrane 
(Tahara and Kanatani, 1996). Most bacteriocins exert 
bactericidal mode of action against the sensitive micro-
organisms, although some of the bacteriocins have been 
shown to act in a bacteriostatic manner. Bactericidal 
activity of bacteriocins may be accompanied by lysis of 
sensitive cells (bacteriolytic bacteriocins), as shown for 
acidocin D20079 (Deraz et al., 2007). Acidocin 1B 
displayed bactericidal action with a maximum viability 
loss of about 2 log cycles, which was achieved in less 
than 60 min when it was added to final activity levels of 
160 and 320 AU/ml. Electron microscopy of the acidocin 
1B treated sensitive cells corroborated that the acidocin 
1B induced cell lysis. This was apparently caused by 
changes in the structure of the cell wall, resulting in the 
rupture of the cells in several places and the escape of 
cell contents. The cell wall ultimately disintegrates, 
leaving debris that was apparently responsible for the 
granular appearance of the observation field (Kyoung-Sik 
et al., 2007). 
 
 
APPLICATION OF ACIDOPHILUS BACTERIOCIN 
 
The application of a purified bacteriocin from bifido-
bacteria directly to food systems has never been reported 
until now but its potential in such an application has not 
been disregarded. Many reports mention about the 
incorporation of acidophilus into different types of foods 
and beverages and their usefulness to human health. 
Acidophilus products includes fermented milk such as 
acidophilus milk, acidophilus yoghurt and sweet acido-
philus milk (Salminen et al., 1996), fruit juice and 
vegetable juice (Tsen et al., 2004 and 2008) and soy milk 
(Apostolidis et al., 2007). Growth of preschool children 
was improved when fed an iron fortified fermented milk 
beverage supplemented with L. acidophilus was given to 
them (Silva et al., 2008). Supplementation with a combi-
nation of B. longum and L. acidophilus has been reported 
to reduce the ecological changes in the intestinal micro-
biota induced by administration of clindamycin (Horrange 
et al., 1994). 
Researchers have proposed the possibility of incurpo-
rating antimicrobial compounds isolated from bifidobac-
teria directly into food systems and pharmaceutical 
products. In contrast to most other bacteriocins pro-
duced by lactic acid bacteria, acidocin B is more inhibit-
tory towards Clostridia than to other lactic acid bacteria, it 





ted products such as cheese or silage (Ten Brink et al., 
1994). The ability to survive acidic conditions, bile resis-
tance, and the production of a bacteriocin that is active 
against food related pathogens and spoilage micro-
organisms, contributes to the ability of L. acidophilus 
30SC as a probiotic culture that may have potential appli-
cations in the production of cultured foods and dietary 
adjuncts (Oh et al., 2000). Acidocin CH5 is unique due to 
its broad activity spectrum and its physico-chemical pro-
perties (Chumchalova et al., 1995). Acidocin CH5 is pro-
duced not only in various laboratory complex broths but 
also in milk, so it can be used in fermented milk products 
to retard the growth of pathogenic bacteria (Chumchalava, 
2004). L. sakei NCDO 2714 was found to be among the 
sensitive strain whose growth was inhibited by acidocin 
20079. This strain is often present in vacuum-packaged 
meat, and can cause anaerobic spoilage if specific hydro-
gen sulphide producing L. sakei strains predominate in 
the environment. Addition of bacteriocins preventing L. 
sakei could therefore be advantageous for meat conser-
vation purposes (Deraz et al., 2005). Acidocin 1B and its 
producer strain, which can endow broad antimicrobial 
activity against a variety of pathogens, may have poten-
tial value as a biopreservative in the various food sys-
tems during long storage periods at different preservatory 
temperatures and pH conditions (Kyoung-Sik et al., 2007). 
In conclusion, acidocin AA11 meets many of the require-
ments proposed by Piard and Desmazeaud for an ideal 
antimicrobial compound. In addition to its inhibition spect-
rum, technological properties (heat and storage stability) 
provide the bacteriocin with an application potential as a 
biopreservative (Abo-Amer 2007). Currently, there are no 
bacteriocins from acidophilus that are being applied 
commercially in food systems as food preservatives. But 
this is not only true for the bacteriocins from acidophilus 
but also true for many bacteriocins isolated from lactic 
acid bacteria. Many bacteriocins have been characterized 
biochemical and genetically but many aspects of these 
compounds are still unknown (Cleveland et al., 2001) 
which explains why till date nisin, approved by the Food 
and Drug Administration, is the only purified bacteriocin 
widely used as a food preservative. Toxicity data exist for 
only a few bacteriocins, none of which are for bacterio-
cins from acidophilus, but research and their long time 
intentional use strongly suggest that bacteriocins can be 
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